MeSH term
Frequency | Condition_Probility | Aged | 25 | 0.0 |
Humans | 139 | 0.0 |
Time Factors | 7 | 0.0 |
Binding Sites | 8 | 0.0 |
Catalytic Domain | 5 | 1.0 |
Cloning, Molecular | 4 | 0.0 |
Crystallography, X-Ray | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Models, Molecular | 5 | 0.0 |
Protein Binding | 7 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Biopsy | 4 | 0.0 |
English Abstract | 13 | 0.0 |
Multigene Family | 2 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 3 | 1.0 |
Tumor Cells, Cultured | 18 | 0.0 |
Cell Adhesion | 3 | 0.0 |
Cell Line | 11 | 0.0 |
Comparative Study | 23 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Gene Expression | 6 | 0.0 |
Immunohistochemistry | 21 | 0.0 |
Research Support, Non-U.S. Gov't | 87 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
Disease Progression | 7 | 0.0 |
Female | 49 | 0.0 |
Genetic Markers | 2 | 0.0 |
Adult | 30 | 0.0 |
Male | 46 | 0.0 |
Matrix Metalloproteinases/genetics/*metabolism | 3 | 37.0 |
Middle Aged | 36 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Tissue Inhibitor of Metalloproteinases/genetics/*metabolism | 2 | 33.0 |
Gelatinase B/*biosynthesis | 3 | 21.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Signal Transduction | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 26 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Animals | 45 | 0.0 |
Chick Embryo | 2 | 0.0 |
Cytokines/physiology | 2 | 1.0 |
Gelatinase B/biosynthesis | 5 | 23.0 |
Cells, Cultured | 20 | 0.0 |
Enzyme Activation | 7 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Macrophages/drug effects/*enzymology | 2 | 20.0 |
Adolescent | 8 | 0.0 |
Cell Count | 2 | 0.0 |
Cell Differentiation | 4 | 0.0 |
Cell Movement | 5 | 0.0 |
Child | 3 | 0.0 |
Child, Preschool | 3 | 0.0 |
Enzyme Precursors/metabolism | 2 | 1.0 |
Gelatinases/metabolism | 5 | 15.0 |
Infant, Newborn | 3 | 0.0 |
Metalloendopeptidases/metabolism | 3 | 4.0 |
Neoplasm Invasiveness | 13 | 1.0 |
Skin/cytology | 2 | 1.0 |
Metalloendopeptidases/genetics/metabolism | 2 | 40.0 |
Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism | 3 | 23.0 |
Tissue Inhibitor of Metalloproteinase-2/genetics/metabolism | 2 | 18.0 |
Gelatinase B/*metabolism | 11 | 33.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Apoptosis | 4 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 8 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Mice | 24 | 0.0 |
Mice, Nude | 6 | 0.0 |
Peritoneal Neoplasms/secondary | 2 | 14.0 |
RNA, Messenger/analysis | 10 | 0.0 |
Transgenes | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Aged, 80 and over | 10 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Metalloendopeptidases/*antagonists & inhibitors | 2 | 7.0 |
Rats | 5 | 0.0 |
Solubility | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 2 | 0.0 |
Prognosis | 9 | 0.0 |
Survival Analysis | 4 | 0.0 |
Tissue Inhibitor of Metalloproteinase-1/biosynthesis | 2 | 13.0 |
Cohort Studies | 2 | 0.0 |
Gelatinase B/*genetics | 4 | 44.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Genotype | 5 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
In Situ Hybridization | 7 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Blotting, Western | 8 | 0.0 |
Down-Regulation | 3 | 0.0 |
Gelatinase B/metabolism | 8 | 14.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Transfection | 6 | 0.0 |
*Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Neoplasm Invasiveness/*physiopathology | 2 | 11.0 |
Cattle | 5 | 0.0 |
In Vitro | 6 | 0.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Gelatinase A/*metabolism | 7 | 21.0 |
Fetal Membranes, Premature Rupture/*metabolism | 2 | 50.0 |
Gelatinase A/metabolism | 2 | 3.0 |
Pregnancy | 5 | 0.0 |
Tissue Inhibitor of Metalloproteinase-2/metabolism | 3 | 13.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Matrix Metalloproteinases/*analysis | 2 | 28.0 |
Tissue Inhibitor of Metalloproteinases/*analysis | 2 | 100.0 |
Gene Frequency | 2 | 0.0 |
Phenotype | 7 | 0.0 |
Collagen/metabolism | 3 | 1.0 |
Gels | 2 | 2.0 |
Receptors, Collagen | 2 | 2.0 |
Analysis of Variance | 2 | 0.0 |
Gelatinase A/biosynthesis | 2 | 12.0 |
Matrix Metalloproteinases/*biosynthesis | 2 | 18.0 |
Rats, Wistar | 2 | 0.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Enzyme Induction | 4 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Gelatinase B/genetics/*metabolism | 2 | 28.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Gelatinase B/genetics/metabolism | 2 | 16.0 |
Base Sequence | 11 | 0.0 |
DNA Primers | 4 | 0.0 |
Matrix Metalloproteinases/metabolism | 3 | 6.0 |
*Neoplasm Invasiveness | 3 | 4.0 |
Cell Division | 9 | 0.0 |
Neoplasm Proteins/*metabolism | 3 | 0.0 |
Gelatinase A/analysis | 2 | 18.0 |
Gelatinase B/analysis | 4 | 23.0 |
Neoplasm Staging | 3 | 0.0 |
Survival Rate | 3 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Gelatinase A/biosynthesis/genetics | 2 | 16.0 |
Glomerular Mesangium/cytology/*enzymology | 2 | 50.0 |
Amino Acid Sequence | 8 | 0.0 |
Databases, Factual | 2 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Nerve Sheath Tumors/*genetics | 2 | 20.0 |
Neurofibromatosis 1/*genetics | 2 | 1.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 2 | 3.0 |
Collagenases/metabolism | 3 | 8.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Stromelysin 1/metabolism | 2 | 13.0 |
Cell Division/drug effects | 2 | 0.0 |
Collagen/genetics/metabolism | 2 | 13.0 |
Cyclosporine/*pharmacology | 2 | 1.0 |
Extracellular Matrix Proteins/metabolism | 2 | 2.0 |
Glucose/pharmacology | 2 | 1.0 |
Case-Control Studies | 5 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Phenylalanine/*analogs & derivatives/pharmacology | 3 | 16.0 |
Matrix Metalloproteinases/*metabolism | 3 | 7.0 |
Mice, Knockout | 2 | 0.0 |
Tissue Inhibitor of Metalloproteinase-1/metabolism | 2 | 7.0 |
Swine | 2 | 0.0 |
Alleles | 3 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Risk Factors | 2 | 0.0 |
Gelatinase B/genetics | 2 | 13.0 |
Transforming Growth Factor beta/metabolism | 2 | 1.0 |
Metalloendopeptidases/*metabolism | 5 | 5.0 |
Reference Values | 2 | 0.0 |
Transforming Growth Factor beta/*metabolism/pharmacology | 2 | 8.0 |
Collagenases/*biosynthesis/genetics | 2 | 25.0 |
Gelatinase B | 19 | 24.0 |
Coculture Techniques | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Thiophenes/pharmacology | 3 | 8.0 |
Chronic Disease | 3 | 0.0 |
Gelatinase A | 13 | 18.0 |
Interstitial Collagenase | 4 | 9.0 |
3T3 Cells | 2 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
Drug Combinations | 2 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Up-Regulation | 4 | 0.0 |
Cell Line, Tumor | 6 | 0.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Substrate Specificity | 3 | 0.0 |
Collagenases/*metabolism | 3 | 10.0 |
Gelatinases/*metabolism | 2 | 8.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Mutation | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Extracellular Matrix/*enzymology | 2 | 15.0 |
Lymphatic Metastasis | 2 | 0.0 |
Tissue Inhibitor of Metalloproteinases | 4 | 6.0 |
Gelatinase B/*physiology | 2 | 50.0 |
Vascular Endothelial Growth Factor A/metabolism | 3 | 2.0 |
Culture Media, Conditioned/pharmacology | 2 | 1.0 |
Hamsters | 2 | 0.0 |
Tissue Inhibitor of Metalloproteinase-2 | 4 | 14.0 |
Collagenases/*genetics | 2 | 11.0 |
Cell Movement/drug effects | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Interleukin-8/analysis | 2 | 4.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Gelatinase B/*genetics/physiology | 2 | 100.0 |
Vascular Endothelial Growth Factor Receptor-1/*metabolism | 2 | 16.0 |
